LVTX / LAVA Therapeutics N.V. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) LAVA Therapeutics N.V. (Name of Subject Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) LAVA Therapeutics N.V. (Name of Subject Company) LAVA Therapeutics N.V. (Name of Persons Filing Statement) Common shares, nominal value €0.12 per share (Title of Class of Securities) N51517105 (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 10,522,118.

SCHEDULE A INFORMATION CONCERNING MEMBERS OF THE BOARDS OF DIRECTORS AND THE EXECUTIVE OFFICERS OF PURCHASER.

EX-99.(a)(1)(E) Exhibit 99.(a)(1)(E) SCHEDULE A INFORMATION CONCERNING MEMBERS OF THE BOARDS OF DIRECTORS AND THE EXECUTIVE OFFICERS OF PURCHASER. 1. XOMA Royalty Corporation XOMA Royalty Corporation’s primary business is as a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LAVA THERAPEUTICS N.V. (Name of Subject Company (Is

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Shares, with a nominal value of €0.12 Per Share (Title of Class of

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 30,514,142.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents t

Letter of Transmittal To Tender Common Shares LAVA THERAPEUTICS N.V. a Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0

EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Common Shares of LAVA THERAPEUTICS N.V. a Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents the

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Non-Transferable Contractual Contingent Value Right (“CVR”) for Each Share, Which Represents t

Table 1: Transaction Valuation

Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 30,514,142.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALT

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA THERAPEUTICS N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror)) Common Shares, with a nominal value of €0.12 Per Share (Title of Class of Securities) N515171

CONFIDENTIALITY AGREEMENT

EX-99.(d)(2) Exhibit (d) (2) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of June 2, 2025, between LAVA Therapeutics N.V., a company organized under the laws of the Netherlands (the “Company”), and XOMA (US) LLC, a Delaware limited liability company (“Counterparty”). In order to facilitate the consideration and negotiation of a possible negotiated

Offer to Purchase All Outstanding Common Shares LAVA THERAPEUTICS N.V. A Dutch public limited liability company A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to

EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Common Shares of LAVA THERAPEUTICS N.V. A Dutch public limited liability company at A Cash Amount per Share between $1.16 and $1.24, Consisting of a Base Price Per Share of $1.16 and an Additional Price Per Share of up to $0.08, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 LAVA Therapeutics N.V. (Name of Subject Company) LAVA Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 LAVA Therapeutics N.V. (Name of Subject Company) LAVA Therapeutics N.V. (Name of Persons Filing Statement) Common shares, nominal value €0.12 per share (Title of Class of Securities) N51517105 (CUSIP Number of Cla

LAVA Therapeutics N.V. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts)

Exhibit 99.1 LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update August 13, 2025 · Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs · Consummation of acquisition expected to occur in the fourth quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 LAVA Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 82-2745484 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to Commission file number: 00

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right ̶ XOMA Royalty adds milestone and royalty economics associated with two partnered assets ̶

Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right ̶ XOMA Royalty adds milestone and royalty economics associated with two partnered assets ̶ EMERYVILLE, Calif., UTRECHT, The Netherlands, and PHILADELPHIA, Penn, August 4, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ:

Joint Press Release issued by XOMA Royalty Corporation and LAVA Therapeutics N.V. on August 4, 2025.

EX-99.1 Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right -XOMA Royalty adds milestone and royalty economics associated with two partnered assets- EMERYVILLE, Calif., UTRECHT, The Netherlands, and PHILADELPHIA, Penn, August 4, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (“XOMA Royalty”) (NA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2025 LAVA Therapeutics N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 82-2745484 (State or other jurisdiction of incorporation) (Commis

Share Purchase Agreement, dated August 3, 2025, by and among XOMA Royalty Corporation and LAVA Therapeutics N.V.

Exhibit 2.1 SHARE PURCHASE AGREEMENT dated as of August 3, 2025 by and between XOMA ROYALTY CORPORATION And LAVA THERAPEUTICS N.V. Table of Contents Page Article 1 DEFINITIONS 6 Section 1.01 Definitions 6 Section 1.02 Other Definitional and Interpretative Provisions 19 Article 2 THE OFFER 19 Section 2.01 The Offer 19 Section 2.02 Company Action 24 Section 2.03 Equity Awards 25 Section 2.04 Extraor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2025 LAVA Therapeutics N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 3, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 82-2745484 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) LAVA Therapeutics N.V. (Name of Subject Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) LAVA Therapeutics N.V. (Name of Subject Company) LAVA Therapeutics N.V. (Name of Persons Filing Statement) Common shares, nominal value €0.12 per share (Title of Class of Securities) N51517105 (CU

Press Release of XOMA Realty Company and LAVA Therapeutics N.V. dated August 4, 2025.

Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right ̶ XOMA Royalty adds milestone and royalty economics associated with two partnered assets ̶ EMERYVILLE, Calif., UTRECHT, The Netherlands, and PHILADELPHIA, Penn, August 4, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA Therapeutics N.V. (Name of Subject Company (Issue

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA Therapeutics N.V. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror 1)) Ordinary Shares, Par Value €0.12 Per Share (Title of Class of Securities) N5

Share Purchase Agreement, dated August 3, 2025, by and among XOMA Royalty Corporation and LAVA Therapeutics N.V.

Exhibit 2.1 SHARE PURCHASE AGREEMENT dated as of August 3, 2025 by and between XOMA ROYALTY CORPORATION And LAVA THERAPEUTICS N.V. Table of Contents Page Article 1 DEFINITIONS 6 Section 1.01 Definitions 6 Section 1.02 Other Definitional and Interpretative Provisions 19 Article 2 THE OFFER 19 Section 2.01 The Offer 19 Section 2.02 Company Action 24 Section 2.03 Equity Awards 25 Section 2.04 Extraor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LAVA Therapeutics N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 84-2745484 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

Letter from PricewaterhouseCoopers Accountants N.V. to the U.S. Securities and Exchange Commission, dated May 23, 2025.

Exhibit 16.1 May 23, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by LAVA Therapeutics N.V. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of LAVA Therapeutics N.V. dated May 20, 2025. We agree with the statements concerning our Firm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 LAVA Therapeutics N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 84-2745484 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.    ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.    )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.    ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Description of Securities.

EXHIBIT 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2024, LAVA Therapeutics N.V. (the “Company,” “we,” “us,” or “LAVA”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. The following description does not purport to be complete

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from to Commission file number: 001 -4

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of LAVA Therapeutics N.V. Subsidiary Jurisdiction LAVA Therapeutics, Inc. Delaware, United States of America LAVA Therapeutics (Australia) Pty Ltd Queensland, Australia

Employment agreement with Charles Morris

Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective February 6, 2023 (the “Effective Date”), by and between Charles Morris (the “Executive”) and LAVA Therapeutics, Inc. (the “Company”). The Company desires to employ the Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to the Company; and Execu

Employment agreement with Stephen Hurly

Exhibit 10.11 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into effective March 27, 2025 (the “Effective Date”), by and between Stephen Hurly (the “Executive”) and LAVA Therapeutics N.V. (the “Company”) and amends, restates, and supersedes in its entirety the Amended and Restated Employment Agreement between the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 LAVA Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 Not Applicable (State or other jurisdiction of incorporation) (C

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 LAVA THerapeutics, N.V. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, nominal value €0.12 per share, reserved for issuance unde

Incentive Compensation Recoupment Policy.

Exhibit 97.1 LAVA THERAPEUTICS N.V. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee of the Board of Directors (the “Board”) of LAVA Therapeutics N.V. (the “Company”) has determined that it is in the best interests of the Company and its shareholders and other stakeholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Co

Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY LAVA THERAPEUTICS N.V. INTRODUCTION Article 1 This document sets out the Company's insider trading policy (“Policy”). DEFINITIONS AND INTERPRETATION Article 2 2.1 In this Policy the following definitions shall apply: Article An article of this Policy. Board LAVA Therapeutics N.V.’s board of directors. CEO The Company’s chief executive officer. CFO The Company’s

As filed with the U.S. Securities and Exchange Commission on March 28, 2025

As filed with the U.S. Securities and Exchange Commission on March 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LAVA Therapeutics N.V. (Exact name of Registrant as specified in its charter) The Netherlands 84-2745484 (State or other jurisdiction of Incorporation or organizatio

Amended and Restated English translation of Articles of Association of LAVA Therapeutics N.V.

Exhibit 3.1 This is a translation into English of the official Dutch version of the articles of association of a limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail. ARTICLES OF ASSOCIATION LAVA Therapeutics N.V. DEFINITIONS AND INTERPRETATION Article 1 1.1 In these articles of association the following definitions

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Exhibit 99.1 LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update · Focused on the evaluation of strategic alternatives · Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 · Phase 1 enrollment in LAVA-1266 clinical trial und

Employment agreement with Fred Powell

Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective November 1, 2022 (the “Effective Date”), by and between Fred Powell (the “Executive”) and LAVA Therapeutics, Inc. (the “Company”). The Company desires to employ the Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to the Company; and Executiv

2021 Long Term Incentive Plan and form of Award Agreement

Exhibit 10.9 LONG-TERM INCENTIVE PLAN LAVA THERAPEUTICS N.V. INTRODUCTION Article 1 1.1 This document sets out the Company's long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: 1. to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LAVA Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 Not Applicable (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 LAVA Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 Not Applicable (State or other jurisdiction of incorporation)

LAVA Announces Evaluation of Strategic Options Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024

Exhibit 99.1 LAVA Announces Evaluation of Strategic Options Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 Utrecht, The Netherlands, and Philadelphia, PA, US – February 25, 2025 – LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its propri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 LAVA Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 LAVA Therapeutics N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40241 Not Applicable (State or other jurisdiction of incorporation) (

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Exhibit 99.3 LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 ●Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207 ●Fourth quarter pipeline advances include initiation o

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Inter

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 (Commission File No. 001-40241) LAVA The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) In

Press Release dated August 20, 2024

Exhibit 99.3 LAVA Reports Second Quarter 2024 Financial Results and Business Update ● Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination ● Favorable safety profile for LAVA-1207 ● Next data update for LAVA-1207 program expected in Q4 2024 ● Strong balance sheet with cash of $86.8 million s

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Six Months Ended June 30, 2024 and 2023

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Inter

Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the Three and Six Months Ended June 30, 2024 and 2023

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Commission File No. 001-40241) LAVA Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) Indi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 (Commission File No. 001-40241) LAVA Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 6, 2024 (Commission File No. 001-40241) LAVA Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 6, 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) In

2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,”

Exhibit 99.1 Gamma-delta T cell engagers for next-generation cancer therapeutics Investor Presentation June 2024 ©2024 LAVA Therapeutics. All rights reserved. 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,”

Press Release dated May 21, 2024

Exhibit 99.3 LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results ● LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 ● Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 ● LAVA-1266 on track for Q2 2024 IND submission ● St

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three Months Ended March 31, 2024 and 2023

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Inter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Commission File No. 001-40241) LAVA Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) Indicat

Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the Three Months Ended March 31, 2024 and 2023

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 (Commission File No. 001-40241) LAVA Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indi

Press Release, dated March 20, 2024

Exhibit 99.1 LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results ● LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024 ● In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) ● LAVA 1266 tracking to Q2 2024 IND submission ● Strong balance sheet

Description of Securities

EXHIBIT 2.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2023, LAVA Therapeutics N.V. (the “Company,” “we,” “us,” or “LAVA”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. The following description does not purport to be complete

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Steve Hurly, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Table of Contents As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-256655) and Form F-3 (No. 333-264246) of LAVA Therapeutics N.V. of our report dated March 20, 2024 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Accountants N.V. Eindhoven, T

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fred Powell, Chief Financial Officer of the Company,

Incentive Compensation Recoupment Policy

EXHIBIT 97.1 LAVA THERAPEUTICS N.V. Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee of the Board of Directors (the “Board”) of LAVA Therapeutics N.V. and its affiliates (the “Company”) has determined that it is in the best interests of the Company and its shareholders and other stakeholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) pr

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Hurly, Director and Chief Executive Officer of

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Fred Powell, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

LVTX / LAVA Therapeutics N.V. / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B

Joint Filing Agreement

EX-99.1 2 tm245846d7ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, $0.14 pa

LVTX / LAVA Therapeutics N.V. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm245846d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) lAVA THERAPEUTICS N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Profit and Loss and Comprehensive Profit and Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Conden

LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.3 LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ● LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2 ● Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody® platform as a monotherapy in advanced EGFR expressing sol

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Commission File No. 001-40241) LAVA The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) In

LVTX / LAVA Therapeutics NV / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Inter

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.3 LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ● Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 ● Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by Seagen ● Portfolio reprioritization and extension of cash runway

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Commission File No. 001-40241) LAVA Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) Indi

Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking wor

Exhibit 99.01 Gamma-delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation August 2023 Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Commission File No. 001-40241) LAVA Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Ind

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 (Commission File No. 001-40241) LAVA Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indic

LAVA THERAPEUTICS PROVIDES UPDATES ON CLINICAL PROGRAMS AND EXTENDS THE CASH RUNWAY ● LAVA-1207 for the treatment of prostate cancer will continue as the lead program ● LAVA-051 Phase 1/2a clinical trial will be discontinued ● Associated cost savings

Exhibit 99.1 LAVA THERAPEUTICS PROVIDES UPDATES ON CLINICAL PROGRAMS AND EXTENDS THE CASH RUNWAY ● LAVA-1207 for the treatment of prostate cancer will continue as the lead program ● LAVA-051 Phase 1/2a clinical trial will be discontinued ● Associated cost savings and initiatives are expected to extend the cash runway further into 2026 Utrecht, The Netherlands, and Philadelphia, USA – June 14, 2023

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Inter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 (Commission File No. 001-40241) LAVA Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive office) Indica

LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.3 LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS ● Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA ● Strong balance sheet expected to provide cash runway into 2026 Utrecht, The Netherlands, and Philadelphia, USA – June 8, 2023 – LAVA Therapeutics N.V. (Nasdaq: LVTX), a c

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

LVTX / LAVA Therapeutics NV / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B

Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking wor

Exhibit 99.1 Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation April 2023 Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-40241) LAVA Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indi

LAVA Therapeutics N.V. Condensed Consolidated Statements of Loss (unaudited) (in thousands, except share and per share amounts)

Exhibit 99.1 LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS ● Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma ● Initial clinical data for L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-40241) LAVA Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 62 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indi

As filed with the Securities and Exchange Commission on April 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Table of Contents As filed with the Securities and Exchange Commission on April 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Fred Powell, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Description of Securities

EXHIBIT 2.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, LAVA Therapeutics N.V. (the “Company,” “we,” “us,” or “LAVA”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. The following description does not purport to be complete

Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Steve Hurly, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Clinical Supply Agreement, dated as of January 27, 2023, by and between LAVA Therapeutics, Inc. and Seagen, Inc.

Certain portions of this exhibit (indicated by “[***]”) have been excluded because they are both not material and are the type that the registrant treats as private or confidential.

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Hurly, Director and Chief Executive Officer of

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-256655) and Form F-3 (No. 333-264246) of LAVA Therapeutics N.V. of our report dated April 11, 2023 relating to the financial statements, which appears in this Form 20-F. /s/ drs. J.W. Middelweerd PricewaterhouseCoopers Account

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fred Powell, Chief Financial Officer of the Company,

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

Exhibit 99.1 LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors Utrecht, The Netherlands and Philadelphia, Pa., USA – February XX, 2023 – LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 (Commission File No. 001-40241) LAVA Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Utrecht, The Netherlands (Address of principal executive offices) Indi

LVTX / LAVA Therapeutics NV / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium ● Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release synd

Exhibit 99.1 LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium ● Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicities ● Preliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of

Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking wor

Exhibit 99.2 Gamma delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation February 2023 Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 (Commission File No. 001-40241) LAVA The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Utrecht, The Netherlands (Address of principal executive offices) I

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Exhibit 99.1 LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer UTRECT, The Netherlands and PHILADELPHIA, February 6, 2023 - LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 (Commission File No. 001-40241) LAVA The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Utrecht, The Netherlands (Address of principal executive offices) I

Legal Disclosure: Forward - looking Statements 2 This presentation contains statements that constitute forward - looking statements . Many of the forward - looking statements contained in this presentation can be identified by the use of forward - lo

EX-99.1 2 tmb-20230109xex99d1.htm EX-99.1 Exhibit 99.1 Gamma delta T cell engagers for the development of next - generation cancer therapeutics Corporate presentation January 2023 Legal Disclosure: Forward - looking Statements 2 This presentation contains statements that constitute forward - looking statements . Many of the forward - looking statements contained in this presentation can be identif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-40241) LAVA Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices) I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-40241) LAVA Ther

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive office

LAVA Therapeutics Announces Appointment of New Directors to the Board Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board

Exhibit 99.1 LAVA Therapeutics Announces Appointment of New Directors to the Board Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board Utrecht, The Netherlands and Philadelphia, Pa., USA ? January 6, 2023 ? LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody? platform of bispecific gamma delta T cell engagers,

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Fred Powell, Chief Financial Officer of the Company

As filed with the Securities and Exchange Commission on December 23, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Amendment No. 1)

Table of Contents As filed with the Securities and Exchange Commission on December 23, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Fred Powell, certify that: 1. I have reviewed this annual report on Form 20-F/A of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to

Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Steve Hurly, certify that: 1. I have reviewed this annual report on Form 20-F/A of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.1 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Hurly, Director and Chief Executive Officer o

Fax: 215.864.8999

CORRESP 1 filename1.htm Fax: 215.864.8999 [email protected] Mary J Mullany Tel: 215.864.8631 Fax: 215-864-8999 [email protected] December 12, 2022 By EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, D.C. 20549 Attn: Tara Harkins Eric Atallah Re: LAVA Therapeutics N.V. Form 20-F for the Fiscal Year Ended Decembe

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Exhibit 99.3 LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results ● LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual Meeting ● Presented LAVA-051 clinical pharmacodynamic data demonstratin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (Commission File No. 001-40241) LAVA The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices)

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Profit and Loss and Comprehensive Profit and Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Conden

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

NL0015000AG6 / LAVA THERAPEUTICS NV COMMON STOCK / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-40241) LAVA Th

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offi

Exclusive License Agreement, dated as of September 23, 2022, by and between LAVA Therapeutics, Inc. and Seagen, Inc.

CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH ?[***]? BECAUSE IT IS NOT MATERIAL AND IS INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Exhibit 99.1 Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors ?Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vg9Vd2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors ? ?LAVA to Receive

2 Legal Disclosure: Forward - looking Statements This presentation contains forward - looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials . Words such

Exhibit 99.2 1 Fighting Cancer with Precision Gammabody ? Platform Corporate Presentation September 2022 2 Legal Disclosure: Forward - looking Statements This presentation contains forward - looking statements, including with respect to the company?s anticipated growth and clinical development plans, including the timing of clinical trials .. Words such as ?anticipate,? ?believe,? ?could,? ?will,?

NL0015000AG6 / LAVA THERAPEUTICS NV COMMON STOCK / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, par value $0.14 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Exhibit 99.3 ? LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results ? ? Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth quarter 2022 ? ? Enrollment continuing in LAVA-1

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management?s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ? Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Int

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-40241) LAVA Th

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-40241) LAVA Therape

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices)

0000573236_2 R1.0.0.24 Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting: The Notice of Annual General Meeting is available at www.proxyvote.com LAVA Therapeutics N.V. Annual General Meeting of Shareholders

Exhibit 99.3 11 123456781 234567 81 234567 81 234567 81 234567 81 234567 81 234567 812345678 NAMETHE COMPANY NAME INC. - COMMON123,456,789,012.12345THE COMPANY NAME INC. - CLASS A123,456,789,012.12345THE COMPANY NAME INC. - CLASS B123,456,789,012.12345THE COMPANY NAME INC. - CLASS C123,456,789,012.12345THE COMPANY NAME INC. - CLASS D123,456,789,012.12345THE COMPANY NAME INC. - CLASS E123,456,789,0

Utrecht, The Netherlands and Philadelphia, USA – May 31, 2022

Exhibit 99.1 Utrecht, The Netherlands and Philadelphia, USA ? May 31, 2022 ? LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody? platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Annual General Meeting of Shareholders will take place on Wednesday, June 15,

CONVENING NOTICE

Exhibit 99.2 CONVENING NOTICE ? This is the convening notice for the annual general meeting of shareholders of LAVA Therapeutics N.V. (the "Company") to be held on June 15, 2022 at 7:30 am Central European Summer Time at Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). ? The agenda for the AGM is as follows: ? 1.Opening ? 2.Discussion of the annual report over the financial yea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 (Commission File No. 001-40241) LAVA Therapeu

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices) I

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management?s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report, as well as our

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 (Commission File No. 001-40241) LAVA Therapeu

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices) I

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

Exhibit 99.3 ? LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results ? ? LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual Meeting ? ? LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed th

LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ? Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position (unaudited) 3 Condensed Consolidated Interim Statements of Changes in Equity (unaudited) 4 Condensed Consolidated Int

LAVA Therapeutics N.V. Yalelaan 60 3584 CM Utrecht The Netherlands

LAVA Therapeutics N.V. Yalelaan 60 3584 CM Utrecht The Netherlands ? ? April 20, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dorrie Yale ? Re: LAVA Therapeutics NV Registration Statement on Form F-3 Filed April 12, 2022 File No. 333-264246 ? ?? ?? ?? ? ? Ladies and Gentlemen: On behalf of LAVA Therapeuti

As filed with the Securities and Exchange Commission on April 12, 2022

Table of Contents ? ? As filed with the Securities and Exchange Commission on April 12, 2022 Registration No.

Form of Indenture

Exhibit 4.2 LAVA Therapeutics N.V. as the Company and [ ] as Trustee Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 ARTICLE 2 THE SECURITIES Section 2.01. Form and Dating 5 S

Equity Distribution Agreement, dated as of April 11, 2022, between LAVA Therapeutics N.V. and JMP Securities LLC

EX-1.2 2 tmb-20220407xex1d2.htm EX-1.2 Exhibit 1.2 e LAVA THERAPEUTICS N.V. $50,000,000 Common Stock EQUITY DISTRIBUTION AGREEMENT Dated: April 11, 2022 TABLE OF CONTENTS SECTION 1.Description of Securities.‌ SECTION 2.Placements.‌ SECTION 3.Sale of Placement Securities by the Placement Agent‌ SECTION 4.Suspension of Sales‌ SECTION 5.Representations and Warranties.‌ SECTION 6.Sale and Delivery to

Filing Fee Exhibit

Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form F-3 (Form Type) LAVA Therapeutics N.

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Exhibit 99.1 LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results ? - LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022 - LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022 - New pipeline program: LAVA-1266, a CD123-direc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 (Commission File No. 001-40241) LAVA Therap

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices)

Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Steve Hurly, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Edward F. Smith, Chief Financial Officer of the Compa

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. ?333-256655?) of LAVA Therapeutics N.V. of our report dated March 24, 2022 relating to the financial statements, which appears in this Form 20-F. /s/ R.M.N. Admiraal RA ? PricewaterhouseCoopers Accountants N.V. Eindhoven, The Nethe

Description of Securities

EXHIBIT 2.1 ? Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2021, LAVA Therapeutics N.V. (the ?Company,? ?we,? ?us,? or ?LAVA?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares. The following description does not purport to be complet

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EXHIBIT 13.1 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of LAVA Therapeutics N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Hurly, Director and Chief Executive Officer of

As filed with the Securities and Exchange Commission on March 24, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Table of Contents As filed with the Securities and Exchange Commission on March 24, 2022 ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A) OR 15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Edward F. Smith, certify that: 1. I have reviewed this annual report on Form 20-F of LAVA Therapeutics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit t

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Shares, ?0.12 par value per share, of LAVA Therapeutics N.V.

NL0015000AG6 / LAVA THERAPEUTICS NV COMMON STOCK / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm226094d29sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) lAVA THERAPEUTICS N.V. (Name of Issuer) Common Shares, €0.12 par value (Title of Class of Securities) N51517105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ? For the Month of January 2022 ? Commission File Number: 001-40241 ? LAVA Therapeutics N.V. (Translation of registrant?s name into English) ? ? Yalelaan 60 3584 CM Utrecht, the Netherlands (Address of pr

1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation January 2022 2 Legal Disclosure: Forward - looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward - looking statements. Man

Exhibit 99.1 1 Fighting Cancer with Precision Gammabody ™ Platform Corporate Presentation January 2022 2 Legal Disclosure: Forward - looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward - looking statements. Many of the forward - looking statements contain ed in this presentation can be identified by the use of forward - looking words such as “an

LAVA THERAPEUTICS N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Table of Contents Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS ? Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss for the Three and Nine Months Ended September 30, 2021 and 2020 (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position as of September 30, 2021 and December 31, 2020 (unaudited) 3 Co

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 tmb-20211115xex99d2.htm EX-99.2 Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 (Commission File No. 001-40241) LAVA The

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offic

LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS

Exhibit 99.3 ? LAVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER FINANCIAL RESULTS ? - LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022 - LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on track to begin enrolling later this quarter - LAVA-051 granted orphan drug designation by the U

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-40

6-K 1 tmb-20211013x6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-40241 LAVA Therapeutics N.V. (Translation of registrant’s name into English) Yalelaan 60 3584 CM Utrecht, the Netherlands

2 Legal Disclosure: Forward-looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the us

Exhibit 99.1 1 Fighting Cancer with Precision Gammabody? Platform Corporate Presentation October 2021 Exhibit 99.1 2 Legal Disclosure: Forward-looking Statements @lava therapeutics 2021 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 lvtx-ex9928.htm EX-99.2 Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 (Commission File No. 001-40241) LAVA Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices) In

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metasta

Exhibit 99.3 LAVA Therapeutics Provides Business Update and Reports Second Quarter Results Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc. remains on track and p

LAVA THERAPEUTICS N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Exhibit 99.1 LAVA THERAPEUTICS N.V. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Condensed Consolidated Interim Statements of Loss and Comprehensive Loss for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited) 2 Condensed Consolidated Interim Statements of Financial Position as of June 30, 2021 and December 31, 2020 (unaudited) 3 Condensed Consolidated Interim St

As filed with the Securities and Exchange Commission on May 28, 2021

As filed with the Securities and Exchange Commission on May 28, 2021 Registration No.

LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.2 3 lvtx-ex9927.htm EX-99.2 Exhibit 99.2 LAVA THERAPEUTICS, N.V. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this r

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development pla

EX-99.3 4 lvtx-ex9936.htm EX-99.3 Exhibit 99.3 LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key manag

LAVA THERAPEUTICS NV INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

EX-99.1 2 lvtx-ex9918.htm EX-99.1 Exhibit 99.1 LAVA THERAPEUTICS NV INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income (Loss) for the Three Months Ended March 31, 2021 and 2020 2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of March 31, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 (Commission File No. 001-40241) LAVA Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 (Commission File No. 001-40241) LAVA Therapeutics N.V. (Translation of registrant?s name into English) Yalelaan 60 3584 CM Ultrecht, The Netherlands (Address of principal executive offices) Indic

Joint Filing Agreement

EX-99.1 2 d126052dex991.htm EX-99.1 Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Shares of LAVA Therapeutics N.V. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. April 8, 2021 Versant Venture Capital VI, L.P. By: Versant Ventur

Joint Filing Agreement

EX-99.1 2 tm2112372d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Shares, €0.12 p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.   ) lAVA THERAPEUTICS N.V. (Name of Issuer) Common Shares, €0.12 par value (Title of Class of Securities) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.   ) lAVA THERAPEUTICS N.V. (Name of Issuer) Common Shares, €0.12 par value (Title of Class of Securities) N51517105 (CUSIP Number) March 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* LAVA

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* LAVA THERAPEUTICS N.V. (Name of Issuer) Common Shares, nominal value €0.12 per share (Title of Class of Securities) N51517105 (CUSIP Number) Versan

JOINT FILING AGREEMENT

EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, nominal value €0.12 per share (Title of Class of S

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LAVA Therapeutics N.V. (Name of Issuer) Common Shares, nominal value €0.12 per share (Title of Class of Securities) N51517 105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LAVA Therapeutics N.V.1 (Name of Issuer) Common Shares, €0.12 par value (Title of Class of Securities) (CUSIP Number) March

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LAVA Therapeutics N.V.1 (Name of Issuer) Common Shares, €0.12 par value (Title of Class of Securities) N51517105 (CUSIP Number) March 25, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

Exhibit 99.1 Form of Lock-Up Agreement, dated as of February 24, 2021 between Novo Holdings A/S and the Underwriters.

EX-99.1 Exhibit 99.1 FORM OF LOCK-UP AGREEMENT February 24, 2021 J.P. MORGAN SECURITIES LLC JEFFERIES LLC SVB LEERINK LLC As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o SVB Leerink LLC 1301 Avenue of th

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* LAVA THERAPEUTICS

SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* LAVA THERAPEUTICS N.V. (Name of Issuer) Common shares, €0.12 nominal value per share (Title of Class of Securities) N51517105 (CUSIP number) M.O.J.M. Perret Coop

Simplified overview of cells involved in innate and adaptive immunity

Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-253795 Prospectus 6,700,000 shares LAVA Therapeutics B.V. to be converted and renamed LAVA Therapeutics N.V. (incorporated in the Netherlands) Common shares We are offering our common shares. This is our initial public offering and no public market currently exists for our common shares. The initial public offering price is $1

- F-1/A

Table of Contents As filed with the Securities and Exchange Commission on March 23, 2021 Registration No.

* * * *

Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR March 23, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Al Pavot Mr. Chris Edwards Mr. Tim Buchmiller Re: LAVA Therapeutics B.V. Amendment No. 1 to Registration Statement on Form F-1 Filed on March 18, 2021 File No. 333-253795 Ladies and Ge

[Signature Page to Underwriters’ Acceleration Request]

J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Jefferies LLC 520 Madison Avenue New York, NY 10022 SVB Leerink LLC 1301 Avenue of the Americas, 12th floor New York, NY 10019 March 22, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: LAVA Therapeutics B.V. Registration Statement on Form F-1 (File N

[Signature Page Follows]

Yalelaan 60 VIA EDGAR 3584 CM Utrecht The Netherlands March 22, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Al Pavot Mr. Chris Edwards Mr. Tim Buchmiller Re: LAVA Therapeutics B.V. Registration Statement on Form F-1 File No. 333-253795 Acceleration Request Requested Date: March 24, 2021 Requested

Powers of attorney (included on signature page to the registration statement).

Table of Contents As filed with the Securities and Exchange Commission on March 18, 2021 Registration No.

2020 U.S. Stock Option Plan.

Exhibit 10.6 TERMS AND CONDITIONS of the U.S. STOCK OPTION PLAN relating to shares in the capital of: LAVA THERAPEUTICS B.V. 1 TABLE OF CONTENTS Article 1 Definitions 3 Article 2 Option Plan 7 Article 3 Effective Date. Term 8 Article 4 Authority of the Board 8 Article 5 Eligibility and Participation 9 Article 6 Shares 9 Article 7 Granting, vesting and terms of Options 10 Article 8 Internal Reorgan

English translation of Articles of Association of LAVA Therapeutics N.V.

EX-3.2 4 d21431dex32.htm EX-3.2 Exhibit 3.2 1 Draft dated March 17, 2021 This is a translation into English of the official Dutch version of the articles of association of a public company with limited liability under Dutch law. Definitions included in Article 1 below appear in the English alphabetical order, but will appear in the Dutch alphabetical order in the official Dutch version. In the eve

Form of Code of Business Conduct and Ethics of the Registrant

Exhibit 14.1 1 CODE OF BUSINESS CONDUCT AND ETHICS LAVA THERAPEUTICS N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s code of business conduct and ethics, consisting of the principal business, ethical, moral and legal standards which the Company Group and all Employees and Officers are expected to observe. 1.2 This policy shall be posted on the Website. DEFINITIONS AND INTERPRE

Form of Indemnification Agreement for non-executive directors.

Exhibit 10.4 INDEMNIFICATION AGREEMENT between [name] as the Officer and LAVA Therapeutics N.V. as the Company 2 TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 3 1.1 Definitions 3 1.2 Interpretation 5 2 INDEMNIFICATION AND INSURANCE 6 2.1 Entitlement to indemnification 6 2.2 Advancements 6 2.3 Limitations 7 2.4 Determination of entitlement to indemnification and advancements 7 2.5 Proceedings

Form of Indemnification Agreement for executive directors and executive officers.

Exhibit 10.3 INDEMNIFICATION AGREEMENT between [name] as the Officer and LAVA Therapeutics N.V. as the Company 2 TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 3 1.1 Definitions 3 1.2 Interpretation 5 2 INDEMNIFICATION AND INSURANCE 6 2.1 Entitlement to indemnification 6 2.2 Advancements 6 2.3 Limitations 7 2.4 Determination of entitlement to indemnification and advancements 7 2.5 Proceedings

Form of internal rules of the board of directors of LAVA Therapeutics N.V., as they will be in effect immediately following the completion of our corporate reorganization.

Exhibit 3.3 1 BOARD RULES LAVA THERAPEUTICS N.V. INTRODUCTION Article 1 1.1 These rules govern the organisation, decision-making and other internal matters of the Board. In performing their duties, the Directors shall comply with these rules. 1.2 These rules shall be posted on the Website. DEFINITIONS AND INTERPRETATION Article 2 2.1 In these rules the following definitions shall apply: Article An

2018 Stock Option Plan.

Exhibit 10.5 TERMS AND CONDITIONS of the STOCK OPTION PLAN relating to depositary receipts for shares in the capital of: LAVA THERAPEUTICS B.V. 1 TABLE OF CONTENTS Article 1 Definitions 3 Article 2 Option Plan 7 Article 3 Effective Date 7 Article 4 Authority of the Board 7 Article 5 Eligibility and Participation 8 Article 6 Foundation 8 Article 7 Depositary Receipts 9 Article 8 Granting and Terms

Form of Underwriting Agreement.

Exhibit 1.1 LAVA Therapeutics B.V. [•] Common Shares, Nominal Value €0.12 Underwriting Agreement [•], 2021 J.P. Morgan Securities LLC Jefferies LLC SVB Leerink LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o SVB Leerink LLC 1301 Avenu

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 LAVA Therapeutics B.V.* (Exact name of registrant as specified in its charter) The Netherlands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identif

English translation of Articles of Association of LAVA Therapeutics B.V. as they are in effect prior to completion of our corporate reorganization.

Exhibit 3.1 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so the Dutch text shall prevail. AMENDMENT OF ARTICLES OF ASSOCIATION LAVA THERAPEUTICS B.V. This day, the fifteenth of September two thousand twenty, the following person appears before me, Cornelis Johannes Joz

2021 Employee Share Purchase Plan

EX-10.8 14 d21431dex108.htm EX-10.8 Exhibit 10.8 LAVA THERAPEUTICS N.V. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 15, 2021 APPROVED BY THE STOCKHOLDERS: MARCH , 2021 IPO DATE: MARCH , 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase Shares. The

Consent of Karen J. Wilson, director nominee

Exhibit 99.1 Consent of Director Nominee Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, in connection with the registration statement on Form S-1 (the “Registration Statement”) of LAVA Therapeutics, B.V. (the “Company”), the undersigned hereby consents to being named as an individual to become a director of the Company in the Registration Statement and any and all a

* * * *

Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR March 18, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Al Pavot Mr. Chris Edwards Mr. Tim Buchmiller Re: LAVA Therapeutics B.V. Registration Statement on Form F-1 Filed on March 2, 2021 File No. 333-253795 Ladies and Gentlemen: On behalf o

2021 Long Term Incentive Plan and form of Award Agreement.

Exhibit 10.7 LONG-TERM INCENTIVE PLAN LAVA THERAPEUTICS N.V. INTRODUCTION Article 1 1.1 This document sets out the Company’s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2 The main purposes of this Plan are: a. to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote

Amended and Restated Shareholders Agreement, dated as of September 15, 2020, by and among Lava Therapeutics, B.V. and certain Shareholders named therein.

Exhibit 4.1 EXECUTION COPY AMENDED AND RESTATED SHAREHOLDERS AGREEMENT BETWEEN (1) Vesuvius Holding B.V. (2) Mr Erik van den Berg (3) Co?peratieve Gilde Healthcare IV U.A. (4) Versant Venture Capital VI L.P. (5) Versant Vantage I, L.P. (6) MRL Ventures Fund, LLC (7) Novo Holdings A/S (8) Sanofi Foreign Participations B.V. (9) Ysios BioFund III FCRE (10) BB Pureos Bioventures, LP (11) Redmile Bioph

[***] Certain confidential information contained in this document, marked by bracketed asterisks, has been omitted and filed separately with the Commission pursuant to 17 C.F.R. § 200.83. Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 47

CORRESP 1 filename1.htm Divakar Gupta +1 212 479 6474 [email protected] *FOIA Confidential Treatment Request* Confidential Treatment Requested by LAVA Therapeutics B.V. in connection with Registration Statement on Form F-1 (File No. 333-253795) March 10, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Chris

Research Collaboration and License Agreement, dated as of May 13, 2020, by and among Lava Therapeutics, B.V., and Janssen Biotech, Inc.

EX-10.2 Exhibit 10.2 [***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. EXECUTION VERSION RESEARCH COLLABORATION AND LICENCE AGREEMENT THIS RESEARCH COLLABORATION AND LICENCE AGREEMENT (the “Agreement”) dated as of May 13, 2020 (“Effective Date”

* * * *

CORRESP 1 filename1.htm Divakar Gupta + 1 212 479 6474 [email protected] VIA EDGAR March 2, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Al Pavot Mr. Chris Edwards Mr. Tim Buchmiller Re: LAVA Therapeutics B.V. Draft Registration Statement on Form F-1 Submitted on January 25, 2021 CIK No. 000184074

English translation of Articles of Association of LAVA Therapeutics B.V. as they are in effect prior to completion of our corporate reorganization.

EX-3.1 2 d21431dex31.htm EX-3.1 Exhibit 3.1 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so the Dutch text shall prevail. AMENDMENT OF ARTICLES OF ASSOCIATION LAVA THERAPEUTICS B.V. This day, the fifteenth of September two thousand twenty, the following person appears

Restated and Amended License and Assignment Agreement, dates as of February 25, 2021 by and among LAVA Therapeutics B.V. and Stichting VUmc.

Exhibit 10.1 [***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. RESTATED AND AMENDED LICENSE AND ASSIGNMENT AGREEMENT entered into by and between Stichting VUmc and LAVA Therapeutics B.V. THIS AGREEMENT is entered into with effect as from Februa

Form of Share Issue Deed.

EX-3.4 3 d21431dex34.htm EX-3.4 Exhibit 3.4 DEED OF ISSUE LAVA THERAPEUTICS N.V. THIS DEED IS ENTERED INTO ON [DATE] BY LAVA Therapeutics N.V., a public company with limited liability, having its corporate seat in Utrecht (address: Yalelaan 60, 3584 CM Utrecht, trade register number: 65335740) (the “Company”). NOW HEREBY AGREES AS FOLLOWS 1 DEFINITIONS AND INTERPRETATION 1.1 Definitions 1.1.1 In t

Subsidiaries of the Registrant.

EX-21.1 6 d21431dex211.htm EX-21.1 Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation Lava Therapeutics, Inc. Delaware (United States)

- F-1

Table of Contents As filed with the Securities and Exchange Commission on March 2, 2021 Registration No.

Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation Lava Therapeutics, Inc. Delaware (United States)

EX-21.1 Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation Lava Therapeutics, Inc. Delaware (United States)

DEED OF ISSUE LAVA THERAPEUTICS N.V.

EX-3.4 3 filename3.htm Exhibit 3.4 DEED OF ISSUE LAVA THERAPEUTICS N.V. THIS DEED IS ENTERED INTO ON [DATE] BY LAVA Therapeutics N.V., a public company with limited liability, having its corporate seat in Utrecht (address: Yalelaan 60, 3584 CM Utrecht, trade register number: 65335740) (the “Company”). NOW HEREBY AGREES AS FOLLOWS 1 DEFINITIONS AND INTERPRETATION 1.1 Definitions 1.1.1 In this Deed

-

Table of Contents As confidentially submitted to the Securities and Exchange Commission on January 22, 2021 This draft registration statement has not been publicly filed with the United States Securities and Exchange Commission and all information herein remains strictly confidential.

1

Exhibit 3.1 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so the Dutch text shall prevail. AMENDMENT OF ARTICLES OF ASSOCIATION LAVA THERAPEUTICS B.V. This day, the fifteenth of September two thousand twenty, the following person appears before me, Cornelis Johannes Joz